login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

FDA grants priority review for rivaroxaban supplemental new drug application for the treatment DVT and PE


Tuesday, 10 Jul 2012 12:58

The US Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug applications (sNDAs) filed on 2 May 2012 for rivaroxaban  (Xarelto, Bayer/Janssen), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis(DVT), pulmonary embolism (PE), and to prevent recurrent deep vein thrombosis and pulmonary embolism. 


The FDA grants priority review to medicines that offer major advances in care or provide a treatment where no adequate therapy exists. Under the prescription drug user fee act (PDUFA), FDA will aim to complete its review within six months from the receipt of the sNDA submission, rather than the standard 10 month review cycle.

“We are delighted to have received a priority review designation for Xarelto for the treatment of pulmonary embolism and deep vein thrombosis, and also to prevent the recurrence of these conditions. Each year an estimated 900,000 Americans experience a DVT or PE, and one third of those events are fatal. If approved for these indications, Xarelto has the potential to address critical unmet needs in treating patients with these serious medical conditions,” said Paul Burton, vice president, Cardiovascular Franchise Medical Leader, Janssen R&D.


The submissions are supported by data from the global EINSTEIN programme, which includes two phase 3 studies evaluating the safety and efficacy of rivaroxaban in the treatment of patients with acute symptomatic DVT or PE and the prevention of recurrent events in these patients. A third phase 3 study evaluated the safety and efficacy of rivaroxaban in the long-term prevention of recurrent DVT and PE. In total, these phase 3 studies included more than 9,400 patients.


Separately, Janssen R&D announced it is withdrawing the sNDA for the use of rivaroxaban to reduce the risk of stent thrombosis in patients with acute coronary syndrome (ACS). The company is withdrawing this sNDA because it is contingent on a separate sNDA, for rivaroxaban to reduce of the risk of secondary cardiovascular events in patients with ACS, which Janssen R&D received a complete response letter from the FDA on 21 June 2012. Data from the ATLAS ACS 2 TIMI 51 trial support both sNDAs.


“We remain confident in the overall study results from the ATLAS ACS 2 TIMI 51 trial, including the observed reduction in stent thrombosis that formed the basis for this separate sNDA,” said Burton. “Our top priority is to work with FDA on our original sNDA for ACS and submit our reply to the complete response letter as soon as possible. We plan to resubmit the sNDA for stent thrombosis at the same time.”




Add New Comment

Related Items


Most popular


Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

New deep vein thrombosis guidelines: What you need to know
Thursday, 23 Oct 2014
Suresh Vedantham spoke to Interventional News on the latest from the paper “Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus ... New deep vein thrombosis guidelines: What you need to know

Bioresorbable scaffolds can produce comparable acute results to metal stents
Tuesday, 04 Nov 2014
Speaking at the Asian Society for Vascular Surgery meeting (5–7 September, Hong Kong, China), Andrew Holden commented that studies indicate that bioresorbable scaffolds can produce comparable acute ... Bioresorbable scaffolds can produce comparable acute results to metal stents

Features


Stentoplasty: An “exciting frontier” in spinal augmentation
Thursday, 27 Nov 2014
Stentoplasty, or vertebral body stenting, represents the next step in the evolution of cement spinal augmentation where a stent is placed within the vertebral body followed by infusion of cement. Stentoplasty: An “exciting frontier” in spinal augmentation

CO2 angiography should be more widely used
Thursday, 27 Nov 2014
CO2 angiography can decrease both morbidity and mortality for patients, in certain clinical scenarios. For those driven by economics, the cost of 100cc of CO2 is approximately three cents. Its use is ... CO2 angiography should be more widely used

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions